Tri Locum Partners LP Takes $70.65 Million Position in Intuitive Surgical, Inc. $ISRG

Tri Locum Partners LP acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 153,250 shares of the medical equipment provider’s stock, valued at approximately $70,647,000. Intuitive Surgical makes up approximately 9.9% of Tri Locum Partners LP’s holdings, making the stock its 2nd largest holding.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Draper Asset Management LLC boosted its position in Intuitive Surgical by 41.9% during the fourth quarter. Draper Asset Management LLC now owns 5,029 shares of the medical equipment provider’s stock valued at $2,848,000 after purchasing an additional 1,485 shares during the last quarter. Deutsche Bank AG increased its holdings in Intuitive Surgical by 9.6% during the fourth quarter. Deutsche Bank AG now owns 1,522,191 shares of the medical equipment provider’s stock worth $862,108,000 after buying an additional 132,966 shares during the last quarter. Oppenheimer Asset Management Inc. raised its position in Intuitive Surgical by 29.3% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 71,077 shares of the medical equipment provider’s stock worth $40,255,000 after acquiring an additional 16,119 shares in the last quarter. Robinhood Asset Management LLC acquired a new stake in Intuitive Surgical in the fourth quarter valued at $6,478,000. Finally, KBC Group NV grew its position in shares of Intuitive Surgical by 4.7% in the 4th quarter. KBC Group NV now owns 420,593 shares of the medical equipment provider’s stock valued at $238,207,000 after acquiring an additional 18,697 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analysts remain broadly optimistic about Intuitive Surgical’s long-term prospects. Reports cite an average Wall Street price target of about $484 and one target of $685, implying significant upside from recent levels. The company’s installed da Vinci system base, recurring instrument and accessory revenue, and durable demand support the bullish view. Why Wall Street Thinks Intuitive Surgical Could Rise Intuitive Surgical Price Target
• Positive Sentiment: Management’s second-quarter commentary indicated durable platform demand and higher margin guidance, suggesting that procedure growth and profitability remain structurally attractive despite near-term volatility. ISRG Q2 Earnings Call Signals Durable Demand
• Positive Sentiment: A new awareness campaign with Deion “Coach Prime” Sanders could increase patient understanding of robotic-assisted surgery and support future procedure demand. Why Intuitive Surgical Shares Rose
• Neutral Sentiment: Intuitive Surgical overhauled its bylaws governing director nominations, shareholder proposals, and special meetings. The changes may improve governance clarity but also alter shareholder participation rights; analysts view the revisions alongside the stock’s weakness as part of a potential undervaluation case. Intuitive Surgical Undervaluation and Bylaw Changes
• Neutral Sentiment: Executive vice president Mark Brosius reported two small stock sales under a pre-arranged Rule 10b5-1 plan. Because the transactions represented roughly 2% of his holdings, they are unlikely to materially change the investment case. SEC Insider Trading Filing
• Negative Sentiment: The post-earnings selloff reflects investor caution despite quarterly results that exceeded expectations. Management warned of softer U.S. procedure growth and deferred care, raising concerns about near-term utilization and valuation. Intuitive Surgical Post-Earnings Selloff ISRG Q2 Earnings Call Signals

Wall Street Analysts Forecast Growth

ISRG has been the subject of several recent analyst reports. UBS Group assumed coverage on shares of Intuitive Surgical in a research note on Tuesday. They issued a “neutral” rating and a $500.00 target price for the company. JPMorgan Chase & Co. cut their price objective on Intuitive Surgical from $550.00 to $450.00 and set an “overweight” rating for the company in a research report on Friday, July 17th. Weiss Ratings reissued a “hold (c)” rating on shares of Intuitive Surgical in a report on Tuesday, May 19th. Mizuho set a $500.00 price target on Intuitive Surgical and gave the company a “neutral” rating in a report on Wednesday, July 15th. Finally, Stifel Nicolaus reduced their price objective on shares of Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating for the company in a research report on Friday, July 17th. Twenty-one investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $517.21.

Intuitive Surgical Price Performance

ISRG opened at $353.10 on Thursday. The business has a fifty day simple moving average of $401.70 and a 200 day simple moving average of $454.32. The company has a market capitalization of $124.74 billion, a PE ratio of 40.45, a price-to-earnings-growth ratio of 2.62 and a beta of 1.46. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.The firm had revenue of $2.89 billion for the quarter, compared to analysts’ expectations of $2.83 billion. During the same quarter last year, the business earned $1.81 EPS. The company’s quarterly revenue was up 18.4% compared to the same quarter last year. Equities analysts anticipate that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $424.14, for a total transaction of $169,656.00. Following the transaction, the executive vice president directly owned 5,720 shares of the company’s stock, valued at approximately $2,426,080.80. This trade represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the completion of the sale, the senior vice president directly owned 6,463 shares of the company’s stock, valued at $2,718,014.65. This represents a 46.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,606 shares of company stock worth $2,786,967 over the last 90 days. 0.60% of the stock is currently owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.